CheckMate901 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) (Aktiv)
RACE IT Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (RACE IT) (Aktiv)
Erstlinie
ABACUS Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder (Aktiv)
MK-3475-905 Randomisierte Phase-3-Studie zur Bewertung der Zystektomie mit perioperativer Pembrolizumab und Zystektomie mit perioperativem Enfortumab Vedotin und Pembrolizumab versus Zystektomie allein bei Cisplatin-ineligiblen Teilnehmern mit muskelinvasiver Blase Krebs (KEYNOTE-905/EV-303) (Aktiv)
Zweitlinie oder später
AArau-Studie A Phase IIB study of the tetramodal therapy of T2-T4 Nx MO bladder cancer with hyperthermia combined with chemoradiotherapy following TUR-BT (Aktiv)
BAY 17403 This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received Prior platinum-containing chemotherapy (Aktiv)
BMS CA017078 A study of Chemo only versus Chemo plus Nivo with or without BMS-986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS-986205 in Patients with MIBC (Aktiv)
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
CheckMate901 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) (Aktiv)
GEM3PSCA-01 Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)